Overview
On 20 March 2017, orphan designation (EU/3/17/1860) was granted by the European Commission to Viadoc Business Solutions Limited, United Kingdom, for poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate (also known as CRLX101) for the treatment of ovarian cancer.
Key facts
Active substance |
Poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate
|
Intended use |
Treatment of ovarian cancer
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/17/1860
|
Date of designation |
20/03/2017
|
Sponsor |
Viadoc Business Solutions Limited
C/O Oakwood Corporate Services 1 Ashley Road, 3rd floor Altrincham, Cheshire WA14 2DT United Kingdom Tel. +44 (0)161 942 4702 E-mail: patti@viadoc.net |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: